A Randomized Multicentric, Placebo-controlled, Parallel, Double-blinded clinical trial to evaluate the efficacy of Svarnsaathi (a proprietary formulation enriched with curcumin) in the treatment of Oral Sub-Mucous Fibrosis
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 50
- 试验地点
- 2
- 主要终点
- The measure of mouth opening will be assessed by Vernier calipers measuring inter incisal distance
研究概览
简要总结
Oral submucous fibrosis (OSMF) is a precancerous condition that is associated with significant functional morbidity and an increased risk for malignancy. It initially affects the lamina propria of the oral mucosa and as the disease progresses it involves the submucosa and the deeper tissues including muscles of the oral cavity with resulting loss of fibro-elasticity. The clinical manifestations include blanching and stiffening of the oral mucosa leading to limitation in oral opening. The presence of fibrous bands in lips, cheeks and soft palate is a hallmark of the disease. The disease extends over time to include the oropharynx and the upper third of the oesophagus. The etiology of the disease over the intervening years was thought to be multifactorial and several agents have been implicated, including the consumption of large amounts of chillies, chronic iron, vitamin B-complex deficiency, anaemia, nutritional deficiencies, genetic predisposition, and auto-immune disease, in addition to the mentioned etiologies, the other local irritants like tobacco (smoking and non smoking). The custom among Indians of chewing "pan" (betel leaf with tobacco powder and other ingredients) and also habit of areca nut /Gutkha chewing has led to the assumption that these habits are also the cause of submucous fibrosis. Several pathogenic mechanisms have been proposed, all based on the constituents of areca nut and genetic susceptibility to the disease. Reports on the frequency of encountering OSMF suggests that the disease has rapidly increased in India from an estimated 250,000 in 1980 to 2 million cases in 1993. The reasons for this rapid increase of the disease is believed to be attributed to the commercial marketing strategies of the pan masala industry which produces and markets freeze-dried preparations of areca nut, and the growth in uptake of this habit by young people (Gupta, 1999). Various classification systems for OSMF based on clinical (Warnakulasuriya, 1987), (Maher et al., 1996) and histopathological criteria (Pindborg & Sirsat, 1966) exist. There are no established markers to identify who may be predisposed to the disease nor to identify the risk of malignancy in affected individuals.
研究设计
- 研究类型
- Interventional
- 分配方式
- Computer generated randomization
- 盲法
- Participant and Investigator Blinded
入排标准
- 年龄范围
- 18.00 Year(s) 至 70.00 Year(s)(—)
- 性别
- All
入选标准
- •1.Males and females aged ≥18
- •Participants (or legally acceptable representative) who are voluntarily willing to participate in the study and sign/thumb-stamped the informed consent document
- •Willingness to use the assigned products according to instructions and other study steps, availability for appointments, and likelihood of completing the clinical trial.
- •No concurrent participation in any other oral care clinical study.
- •Oral Inclusion Criteria 1a.
- •Moderate oral submucous fibrosis (defined interincisal distance equal to or greater than 20mm but less than 35mm AND at least one of the following clinical features): a) fibrous banding (ie stiff/leathery mucosa) b) blanching of mucosa c) burning symptoms (>20mm on items 1 or 2 on oral symptoms VAS) 1b.
- •Mild oral submucous fibrosis (defined as interincisal distance equal to or greater than 35mm but less than 45mm AND at least one of the following clinical features) a) fibrous banding (ie stiff/leathery mucosa) b) blanching of mucosa c) burning symptoms (>20mm on items 1 or 2 on oral symptoms VAS).
排除标准
- •Current or prior history of oral cancer.
- •Radiation therapy to the head or neck region.
- •No recent treatment for OSMF, particularly steroids (within 3 months).
- •Medical conditions which in the opinion of the investigator may compromise the subject’s health or the outcome of the study.
- •(eg ischemic heart disease (angina, recent MI, or connective tissue diseases).
- •Observable oral conditions (eg odontogenic infections) contributing to trismus which in the opinion of the investigator may compromise the subject’s health or the outcome of the study.
- •Women who are, or will become, pregnant or lactating during the course of the study.
- •Participants who are not willing to give their consent to participate in the trial Inability to obtain informed consent.
结局指标
主要结局
The measure of mouth opening will be assessed by Vernier calipers measuring inter incisal distance
时间窗: week0 week4 week 8 week12
次要结局
- The measure of oral symptoms particularly oral burning will be assessed by visual analogue scale(week0 week4 week 8 week12)
